What is the appropriate work‑up and management for a patient with unexplained persistent eosinophilia (>1500/µL) suggestive of a paraneoplastic cause?

Paraneoplastic Eosinophilia: Work-up and Management

In a patient with unexplained persistent eosinophilia (>1500/µL) suggestive of a paraneoplastic cause, immediately initiate comprehensive cancer screening with CT chest/abdomen/pelvis while simultaneously excluding clonal hematologic causes through bone marrow evaluation with cytogenetics and molecular testing for tyrosine kinase fusion genes. 1

Initial Diagnostic Approach

The work-up must distinguish between three critical categories: secondary (reactive) eosinophilia from malignancy, clonal myeloid/lymphoid neoplasms with eosinophilia, and other causes 1.

Step 1: Rule Out Clonal Eosinophilia (Priority)

Bone marrow evaluation is essential and should include:

• Morphological assessment with differential count
• Conventional cytogenetic analysis (karyotype)
• FISH or molecular testing for tyrosine kinase fusion genes: FIP1L1-PDGFRA (4q12), PDGFRB (5q32), FGFR1, and ETV6-ABL1 1, 2
• Consider Optical Genome Mapping (OGM) if conventional karyotype fails or is insufficient 1

Critical point: Identifying these fusion genes is treatment-defining—patients with PDGFRA, PDGFRB, or ETV6-ABL1 rearrangements respond to tyrosine kinase inhibitors 1, 2.

Step 2: Cancer Screening (Concurrent Priority)

CT chest, abdomen, and pelvis with contrast is the initial screening modality of choice 3. This heterogeneous group ranges from benign secondary proliferations to clonal neoplasms 1.

Most common associated malignancies to screen for:

• Small cell lung cancer (most common solid tumor)
• Breast cancer
• Lymphomas (Hodgkin and T-cell lymphomas particularly)
• Ovarian/testicular tumors
• Thymic neoplasms 3, 2

Additional targeted screening:

• Mammogram (and breast MRI if high suspicion) in women 3
• Testicular ultrasound in men (CT has low sensitivity for testicular cancer) 3
• PET-CT if initial CT is negative but clinical suspicion remains high 3

Step 3: Exclude Common Secondary Causes

Before labeling as paraneoplastic, systematically exclude:

• Parasitic infections: Strongyloides stercoralis serology (most common), other helminth serologies based on travel history 4
• Drug reactions: Review all medications, especially NSAIDs, beta-lactams, nitrofurantoin 4
• Allergic/atopic conditions: Asthma, eczema, allergic rhinitis 4
• Autoimmune conditions: ANCA testing for eosinophilic granulomatosis with polyangiitis (EGPA), especially if asthma, rhinosinusitis, or neuropathy present 5

Organ Damage Assessment

Evaluate for eosinophil-mediated end-organ damage regardless of eosinophil count—tissue injury can occur even with moderate eosinophilia 2, 6:

• Cardiac: Echocardiogram and troponin (endomyocardial fibrosis is life-threatening) 2, 6
• Pulmonary: Chest imaging, pulmonary function tests 2
• Neurologic: Clinical examination for peripheral neuropathy; brain imaging if symptoms 5, 6
• Dermatologic: Skin examination and biopsy if lesions present 2
• Gastrointestinal: Consider endoscopy if GI symptoms 2

Management Strategy

If Tyrosine Kinase Fusion Identified:

Initiate imatinib (or appropriate TKI) immediately—these patients have excellent responses 1, 2.

If Paraneoplastic (Cancer Identified):

Treat the underlying malignancy—eosinophilia typically resolves with tumor-directed therapy 2, 7, 6. Bridge with corticosteroids if severe organ involvement while initiating cancer treatment 2.

If Organ Damage Present Without Clear Etiology:

Start systemic corticosteroids immediately (prednisone 0.5-1 mg/kg/day) to prevent irreversible damage, particularly cardiac fibrosis 2, 8. Do not delay treatment waiting for complete diagnostic work-up if organ damage is evident.

If No Cause Identified (Hypereosinophilia of Undetermined Significance):

• Close monitoring with repeat evaluations every 3-6 months 9
• Repeat cancer screening at 6-12 months—occult malignancies may declare themselves over time 9
• Consider corticosteroid trial if symptomatic or progressive 8

Critical Pitfalls to Avoid

1. Do not assume benign cause without bone marrow evaluation—clonal disorders require specific targeted therapy 1
2. Do not rely on peripheral eosinophil count to gauge organ damage severity—significant dysfunction occurs even with moderate eosinophilia 6
3. Do not delay cardiac evaluation—endomyocardial fibrosis is irreversible and potentially fatal 2, 6
4. Do not miss Strongyloides—can cause fatal hyperinfection syndrome if immunosuppressed 4
5. Lymph node biopsy is essential if lymphadenopathy present—lymphoproliferative disorders are common causes 9

Follow-up Protocol

For unexplained cases, structured long-term monitoring is mandatory due to risk of progression to hypereosinophilic syndrome or emergence of occult malignancy 9:

• Repeat complete blood count monthly initially
• Repeat organ assessment every 3-6 months
• Repeat cancer screening at 6-12 months if initially negative
• Consider repeat bone marrow evaluation if clinical evolution occurs